Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
08 May 2023 - 10:30PM
Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
that it will release first quarter 2023 financial results and
business updates on Monday, May 15, 2023. The Company will
host a webcast that day at 8:30 a.m. Eastern Time to
discuss the results and updates.
The live conference call may be accessed
here and on the Company’s website under Events and
Presentations.
The archived webcast will be available on the Company’s website
beginning approximately two hours after the event for 90 days.
About Minerva Neurosciences
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage
biopharmaceutical company focused on developing product candidates
to treat central nervous system (CNS) diseases. Our goal is to
transform the lives of patients with improved therapeutic options.
Minerva’s portfolio of compounds includes roluperidone (MIN-101),
for negative symptoms of schizophrenia, and MIN-301, in
pre-clinical development for Parkinson’s disease. For more
information, please visit our website.
For more information: Investor inquiries: Fred
AhlholmCFO, Minerva Neurosciencesinfo@minervaneurosciences.com
Media Inquiries:Helen ShikPrincipal, Shik Communications LLC
helen@shikcommunications.com
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2024 to May 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From May 2023 to May 2024